期刊文献+

从姑息性治疗转向根治性治疗,时空几何? 被引量:12

下载PDF
导出
摘要 肿瘤,作为人类健康的第二大杀手,其发病率和致死率与经济、生活水平的增长同步。因此,抗击肿瘤成为新世纪人类所面临的一项严峻挑战。肿瘤内科学于20世纪中叶兴起,姑息性治疗延缓了疾病进程,延长了癌症患者的生存期,几十年来化学治疗已成为肿瘤治疗三大手段之一。近年来,一代又一代医药学者的辛勤耕耘使得肿瘤化疗有望走向根性性治疗,其立论寄托在三点:一是祈望临床一线细胞毒药的药剂学、药动学技术变革,靶向制剂和细胞骨架制剂的高选择性和导向性;二是基因工程N肿瘤分子新靶位治疗药的问世,包括利妥昔单抗等;三是酶抑制剂的拓展,涵盖二氢叶酸还原酶抑制剂、拓扑异构酶抑制剂、法尼基转移酶抑制剂等。有鉴于此,癌症从姑息性治疗转向根治性治疗已可寄望。但路漫漫兮,尚待求索,其时间跨度有多长?谁人知晓!
出处 《中国医院用药评价与分析》 2005年第4期200-203,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
  • 相关文献

参考文献7

二级参考文献25

  • 1周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量:51
  • 2Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase Ⅲ trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol, 2001, 19: 1734-1742.
  • 3Schiller JH, Harrington D, Belani CP, et al. For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346: 92-98.
  • 4Mill AB, Hoogstrsten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47: 207-214.
  • 5Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129-137.
  • 6Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79: 538-544.
  • 7Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Reserarsh Award Lecture. Clin Cancer Res, 2000, 6: 747-753.
  • 8Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7: 1459-1465.
  • 9Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21: 2237-2246.
  • 10LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res, 2003, 9:2040-1048.

共引文献48

同被引文献62

引证文献12

二级引证文献150

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部